Abstract
Among the primary causes of cancer-associated death in the world, liver hepatocellular carcinoma (LIHC) ranks the third. LIHC is defined as the sixth most frequently diagnosed carcinoma. The gene mitochondrial carrier 1 (MTCH1) is a protein-coding gene. Recent research suggests that MTCH1 may be associated with some diseases. Here, our study attempts to explore the role and implication of MTCH1 in LIHC. Kaplan Meier Plotter and GEPIA (Gene Expression Profiling Interactive Analysis) databases were employed to determine the expression of MTCH1 and its correlation with prognostic status in LIHC patients. For the first time, our results suggested that MTCH1 was aberrantly expressed in human pan-cancer and highly expressed in LIHC. Its high expression was closely associated with metastasis of tumor, stage of cancer, and poor survival of patients. Then, through enrichment analysis, MTCH1 was found to be closely related to RNA splicing in LIHC. Subsequently, we conducted a series of functional experiments. PCR data showed that LIHC cell lines and samples are highly expressed MTCH1. CCK-8 (Cell Counting Kit-8) assays and Transwell assays indicated that silencing MTCH1 certainly suppressed cell proliferation, migration, and invasion. These findings shed the clue that MTCH1 could be regarded as the potential prognosis biomarker of LIHC and a promising therapeutic target for LIHC.
Highlights
As the International Agency for Research on Cancer reported, liver hepatocellular carcinoma (LIHC) is the third primary inducer amid cancer-associated death worldwide [1]
Based on multiple public databases, we analyzed the high expression of mitochondrial carrier 1 (MTCH1) in LIHC, and its high expression is closely related to tumor metastasis, tumor staging, and poor patient quality of life
Expressed MTCH1 was found in LIHC samples and cell lines
Summary
As the International Agency for Research on Cancer reported, liver hepatocellular carcinoma (LIHC) is the third primary inducer amid cancer-associated death worldwide [1]. LIHC is considered the sixth most diagnosed carcinoma [2, 3]. Chemotherapy, surgical resection, and liver transplantation are effective methods for the early stage of LIHC [4]. Treatment strategies are limited to advanced-stage cases [5]. Compared to early primary LIHC, distant metastasis in the advanced stage is the pivotal inducer of tumor death, because LIHC is a highly aggressive and complex neoplasm disease [6,7,8]. No specific treatment strategy that focuses on LIHC has been developed.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
